Sebastian Grosicki

机构：Medical University of Silesia · ORCID：0000-0003-2644-1050

发表论文 425 篇 · 总被引 17131 次 · h-index 51

代表论文

• Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (2025 · Journal of Clinical Oncology · 被引 18)
• Durable efficacy and long-term safety with pelabresib plus ruxolitinib in JAK Inhibitor–Naive myelofibrosis: 96-week Results from the Phase III MANIFEST-2 study (2025 · Blood · 被引 6)
• Bexobrutideg (NX-5948), a novel Bruton's tyrosine kinase (BTK) degrader, demonstrates rapid and durable clinical responses in Relapsed/Refractory chronic lymphocytic leukemia (CLL): New and updated findings from an ongoing Phase 1a/b trial (2025 · Blood · 被引 5)
• Talquetamab–Daratumumab in Relapsed or Refractory Myeloma (2026 · New England Journal of Medicine · 被引 4)
• Odronextamab plus chemotherapy in patients with previously untreated follicular lymphoma: First results from part 1 of the Phase 3 Olympia-2 study (2025 · Blood · 被引 2)
• Pirtobrutinib vs ibrutinib in treatment-naïve and relapsed/refractory CLL/SLL: Results from the first randomized phase III study comparing a non-covalent and covalent BTK inhibitor (2025 · Blood · 被引 2)